Bitget Lists NodeOps (NODE) for Spot Trading
NodeOps is building a full-stack solution to make make decentralized computing simple, reliable, and accessible at scale. Its architecture is built on two layers: the foundational NodeOps Network protocol, which coordinates decentralized physical infrastructure (DePIN), and a suite of user-facing products, including NodeOps Cloud, Console, Agent Terminal, Staking Hub, and Security Hub, that streamlines deployment and management. At the core of the ecosystem is the NODE token, which powers coordination, rewards real work, and governs the network. With a revenue-backed mint-and-burn model, NODE ensures sustainable value, secures the infrastructure, and enables access to premium features, aligning incentives and supporting long-term growth across the NodeOps ecosystem. NodeOps Network has built the foundation for sustainable infrastructure coordination that scales with actual demand while maintaining the decentralization and cost advantages that make Web3 infrastructure superior to traditional cloud services.
Bitget continues to expand its offerings, positioning itself as a leading platform for cryptocurrency trading. The exchange has established a reputation for innovative solutions that empower users to explore crypto within a secure CeDeFi ecosystem. With an extensive selection of over 800 cryptocurrency broadening and a commitment to broaden its offerings to more than 900 trading pairs, Bitget connects users to various ecosystems, including Bitcoin, Ethereum, Solana, Base, and TON. The addition of NodeOps into Bitget's portfolio marks a significant step toward expanding its ecosystem by embracing niche communities and fostering innovation in decentralized economies, further solidifying its role as a gateway to diverse Web3 projects and cultural movements.
For more details on NodeOps, visit here.
About Bitget
Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, token swap, NFT Marketplace, DApp browser, and more.
Bitget is at the forefront of driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency.
For media inquiries, please contact: media@bitget.com
Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
Hologic 's HOLX Molecular Diagnostics business posted a 7.8% (excluding COVID-19-related sales) growth in the second quarter of fiscal 2025, although results did not reflect its full performance was impacted by lower HIV testing sales in Africa due to significant funding cuts to USAID programs by the new administration. This $50 million annual revenue stream is now being conservatively excluded from the full fiscal outlook. Management noted that without this setback, molecular revenues would have grown at a low double-digit rate in the second quarter. Even so, the long-term trajectory of the segment remains strong. Molecular Diagnostics continues to be the principal growth driver within Hologic's Diagnostics division, with more than 20 assays running on the Panther and Panther Fusion platforms. The company is focused on driving more utilization of its existing menu, such as the test for Mycoplasma Genitalium (MGen), a prevalent but under-screened sexually transmitted disease (STD). Hologic's revenue growth strategy rests on using both lab-sales force and physician-sales force to team up with lab customers, promote screening guidelines and drive test adoption. Newer innovations, like the BV/CV/TV assay, have meaningfully contributed to growth and still offer room for more expansion. Vaginitis affects nearly 20 million women annually in the United States, yet fewer than 40% are tested. Hologic is addressing this gap by driving awareness and securing reimbursement for this high-throughput test, solidifying its position in this space. Another key asset is Biotheranostics, which Hologic acquired in 2021 to enter the fast-growing oncology adjacency. Biotheranostics' unique Breast Cancer Index test continues to see higher adoption, helping determine the benefits of extended endocrine therapy. Our model projects bullish growth for Hologic's Molecular Diagnostics arm, which is likely to expand at a compound annual growth rate (CAGR) of 7.3% during the 2025-2027 period. The Case for Hologic's Rivals Roche 's RHHBY infectious disease business was also affected by the USAID funding pause for testing, causing a decline of 5% in the first quarter of 2025. Still, without this effect, Roche's Molecular Lab grew more than 6%. The company remains optimistic about the funding pause ending and a rebound in this business. This year, Roche is set to launch the cobas BV/CV assay in CE mark countries for use on the cobas 5800/6800/8800 platforms. Abbott ABT is also exposed to the far-reaching implications of the USAID funding halt, which has disrupted the supply chain for essential medical products in underserved countries. Performance-wise, Abbott's Diagnostics business revenues dropped 5% in the first quarter of 2025 due to weak COVID-19 testing sales. The impact of volume-based procurement programs in China led to low single-digit growth in ABT's Core Laboratory Diagnostics. HOLX Stock Performance, Valuation and Estimates In the last 30 days, Hologic shares have risen 3.6% compared to the industry's 0.7% fall. Hologic is trading at a forward five-year sales multiple of 3.44X compared to the industry average of 4.11X. The stock carries a Value Score of B at present. Consensus estimates for Hologic's fiscal 2025 and 2026 earnings are showing a downward trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
Belgravia Hartford Increases Bitcoin (BTC) Treasury Holdings with USD $1 Million Strategic Purchase
Toronto, Ontario--(Newsfile Corp. - July 2, 2025) - Belgravia Hartford Capital Inc. (CSE: BLGV) (OTC Pink: BLGVF) (FSE: ECA) ("Belgravia" or the "Company") is pleased to announce the successful completion of its fourth Bitcoin (BTC) acquisition as part of its long-term Bitcoin Treasury Reserve strategy. This latest purchase further strengthens Belgravia's position as a forward-thinking public company leveraging Bitcoin as a strategic treasury asset. New Bitcoin Acquisition Belgravia Hartford acquired 9.35295508 BTC for a total consideration of USD $1,000,000, executed at an average price of $106,918.08 per Bitcoin (inclusive of all costs and fees). This purchase increases the Company's cumulative Bitcoin holdings to: All figures in USD. The purchase was facilitated through Coinsquare's regulated OTC desk and funded by the previously announced USD $5 million credit facility provided by Round13 Digital Asset Fund L.P.; a premier institutional partner focused on digital asset strategies. Commitment to Transparency and Governance Belgravia Hartford remains committed to full transparency in its treasury operations and will continue to provide timely updates on all material developments. Insiders of the Company currently hold approximately 36% of the outstanding shares, underscoring strong internal alignment with shareholders. Up-to-date insider disclosures are available at ******************************* For legal disclaimers and further corporate information, please visit:
National Post
3 hours ago
- National Post
Belgravia Hartford Increases Bitcoin (BTC) Treasury Holdings with USD $1 Million Strategic Purchase
Article content TORONTO — Belgravia Hartford Capital Inc. (CSE: BLGV) (OTC: BLGVF) (FRA: ECA) ('Belgravia' or the 'Company') is pleased to announce the successful completion of its fourth Bitcoin (BTC) acquisition as part of its long-term Bitcoin Treasury Reserve strategy. Article content This latest purchase further strengthens Belgravia's position as a forward-thinking public company leveraging Bitcoin as a strategic treasury asset. Article content New Bitcoin Acquisition Article content Belgravia Hartford acquired 9.35295508 BTC for a total consideration of USD $1,000,000, executed at an average price of $106,918.08 per Bitcoin (inclusive of all costs and fees). This purchase increases the Company's cumulative Bitcoin holdings to: Article content Description | BTC Amount | USD Value | Average Cost (USD) Article content Previous Holdings | 6.39316479 BTC | $660,094.35 | $103,367.05 per BTC New Purchase | 9.35295508 BTC | $1,000,000.00 | $106,918.08 per BTC Total Holdings | 15.74611987 BTC | $1,660,094.35 | $105,449.46 per BTC Article content All figures in USD. Article content The purchase was facilitated through Coinsquare's regulated OTC desk and funded by the previously announced USD $5 million credit facility provided by Round13 Digital Asset Fund L.P.; a premier institutional partner focused on digital asset strategies. Article content Belgravia Hartford remains committed to full transparency in its treasury operations and will continue to provide timely updates on all material developments. Insiders of the Company currently hold approximately 36% of the outstanding shares, underscoring strong internal alignment with shareholders. Up-to-date insider disclosures are available at Article content Article content Article content Article content Contacts Article content Investor & Media Contact: Article content
